Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncocyte Corp (OCX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 215,688
  • Shares Outstanding, K 51,973
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,750 K
  • 60-Month Beta 6.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 48.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.11
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.46 +19.94%
on 03/25/19
4.58 -9.39%
on 04/11/19
+0.55 (+15.28%)
since 03/18/19
3-Month
1.75 +137.14%
on 01/23/19
6.92 -40.03%
on 01/29/19
+2.35 (+130.56%)
since 01/18/19
52-Week
1.16 +256.22%
on 12/14/18
6.92 -40.03%
on 01/29/19
+1.45 (+53.70%)
since 04/18/18

Most Recent Stories

More News
Research Report Identifies Stamps, Chicken Soup for the Soul Entertainment, Marlin Business Services, OncoCyte, FBL Financial Group, and Cellectis S.A with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stamps.com Inc. (NASDAQ:STMP),...

CMVLF : 20.5900 (+6.41%)
STMP : 79.40 (-0.16%)
MRLN : 22.06 (+1.05%)
OCX : 4.15 (+0.73%)
FFG : 63.37 (-1.68%)
CSSE : 9.84 (+2.50%)
CLLS : 20.09 (+1.06%)
OncoCyte Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

On track for commercial availability of DetermaVu(TM) in 2H 2019

OCX : 4.15 (+0.73%)
OncoCyte to Present Late Breaking Abstract at the American Thoracic Society 2019 International Conference

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that a late breaking abstract has been accepted for a poster presentation...

OCX : 4.15 (+0.73%)
OncoCyte Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 1, 2019 / OncoCyte Corp. (NYSE American: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 1, 2019 at 4:30 PM Eastern...

OCX : 4.15 (+0.73%)
OncoCyte to Report Fourth Quarter and Full-Year 2018 Financial Results on Monday, April 1, 2019

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth...

OCX : 4.15 (+0.73%)
Teladoc to Acquire MedecinDirect, Expand Overseas Business

Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.

TDOC : 51.60 (+3.49%)
OCX : 4.15 (+0.73%)
BEAT : 55.13 (+0.35%)
PRAH : 94.47 (+0.36%)
OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, CEO of OncoCyte Corporation, will be presenting...

OCX : 4.15 (+0.73%)
OncoCyte Announces Initiation of Analytical Validation Study

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the initiation of the Company's Analytical Validation study of DetermaVu(TM)...

OCX : 4.15 (+0.73%)
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX)...

OCX : 4.15 (+0.73%)
OncoCyte Announces Closing of Public Offering of Common Stock

OncoCyte Corporation (NYSE American: OCX) ("OncoCyte"), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the closing of an underwritten public offering....

OCX : 4.15 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade OCX with:

Business Summary

OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

See More

Key Turning Points

2nd Resistance Point 4.41
1st Resistance Point 4.28
Last Price 4.15
1st Support Level 3.98
2nd Support Level 3.81

See More

52-Week High 6.92
Fibonacci 61.8% 4.72
Last Price 4.15
Fibonacci 50% 4.04
Fibonacci 38.2% 3.36
52-Week Low 1.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar